0
Clinical Investigations: COPD |

The Spirometric Efficacy of Once-Daily Dosing With Tiotropium in Stable COPD*: A 13-Week Multicenter Trial

Richard Casaburi, PhD, MD, FCCP; Dick D. Briggs, Jr., MD, FCCP; James F. Donohue, MD, FCCP; Charles W. Serby, MD; Shailendra S. Menjoge, PhD; Theodore J. Witek, Jr., DrPH; for the US Tiotropium Study Group
Author and Funding Information

Affiliations: *From the Harbor-UCLA Research and Education Institute (Dr. Casaburi), Torrance, CA; University of Alabama at Birmingham (Dr. Briggs), Birmingham, AL; University of North Carolina School of Medicine (Dr. Donohue), Chapel Hill, NC; and Boehringer Ingelheim Pharmaceuticals, Inc. (Drs. Serby, Menjoge, and Witek), Ridgefield, CT.,  A complete list of participants in the US Tiotropium Study Group is located in the Appendix.

Correspondence to: Richard Casaburi, PhD, MD, Harbor-UCLA Medical Center, 1000 W Carson St, Torrance, CA 90509; e-mail: casaburi@ucla.edu



Chest. 2000;118(5):1294-1302. doi:10.1378/chest.118.5.1294
Text Size: A A A
Published online

Study objective: To compare the bronchodilator efficacy and safety of tiotropium and placebo.

Design: A 3-month, randomized, double-blind, placebo-controlled, multicenter trial.

Setting: Outpatient.

Patients: Four hundred seventy patients with stable COPD (mean FEV1 = 38.6% predicted).

Interventions: Tiotropium 18 μg (N = 279) or placebo (N = 191) given once daily via a lactose-based dry-powder inhaler device.

Measurements and results: Spirometry was evaluated on days 1, 8, 50, and 92. Data were expressed as the mean trough (ie, before morning dose; 23 to 24 h after previous dose) and average response observed in the 3 h after the dose was received. Tiotropium produced significant improvement in trough FEV1 and FVC, averaging 12% greater than baseline on day 8; these improvements were maintained on days 50 and 92. The average postdose FEV1 was 16% greater than baseline on day 1 and 20% greater than baseline on day 92; FVC was 17% greater than baseline on day 1 and 19% greater than baseline on day 92. Tiotropium was significantly more effective than placebo in both trough and average FEV1 and FVC response (p < 0.001). These spirometric effects were corroborated by significant improvements in daily morning and evening peak expiratory flow rate, as well as a reduction in “as-needed” albuterol use. Symptoms of wheezing and shortness of breath were significantly less in patients receiving tiotropium, and the physician global assessment noted overall improvements with those treated with tiotropium relative to placebo. The most common reported adverse event after tiotropium was dry mouth (9.3% vs 1.6% relative to placebo; p < 0.05).

Conclusions: These data demonstrate that tiotropium is a safe and effective once-daily anticholinergic bronchodilator and should prove useful as first-line maintenance therapy in COPD.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543